Piramal Pharma Limited Reports Strong Financial Results for Q3 and 9M FY25
Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceuticals and wellness company, has revealed its standalone and consolidated financial results for the third quarter (Q3) and the nine months (9M FY25) ended December 2024. The results reflect robust growth across various business sectors, showcasing the company’s resilience and forward momentum.
Financial Highlights for Q3 and 9M FY25
In Q3 FY25, the company reported revenue from operations at ?2,204 crores, which marks a 13% increase from ?1,959 crores in Q3 FY24. For the first nine months of FY25, revenue reached ?6,397 crores, up 14% year-on-year from ?5,619 crores. This growth is heavily driven by the contract development and manufacturing organization (CDMO) sector, which has experienced a remarkable surge in demand.
EBITDA and Profitability Metrics
EBITDA for Q3 FY25 stands at ?350 crores, indicating a 6% growth compared to ?330 crores in the same quarter last year. Furthermore, this number surged to ?977 crores for the nine months period, reflecting a 20% increase from ?815 crores for 9MFY24. The EBITDA margin for Q3 FY25 was reported at 16%, with the nine-month EBITDA margin maintaining a steady 15%.
Net Profit Overview
Piramal Pharma reported a net profit after tax of ?4 crores for Q3 FY25, compared to ?10 crores in Q3 FY24, attributing the decrease to higher operational costs and increased investments in growth initiatives. For the nine months ending December 2024, the net profit stands at a loss of ?62 crores, a reflection of the company’s strategic investments, which aim to enhance future growth.
Key Business Highlights in CDMO and Healthcare
The CDMO sector has been a standout performer, with high-teen revenue growth owing to ongoing partnerships and expansion in commercial manufacturing. Similarly, the Complex Hospital Generics (CHG) division has experienced an uptick in inhalation anesthesia sales, contributing to the strong performance metrics reported.
Sustainable Practices and Innovation
In efforts towards sustainable operations, Piramal Pharma has successfully converted a coal-fired steam boiler at its Digwal facility to use biomass briquettes, which will significantly reduce overall greenhouse gas emissions by approximately 24,000 tons of CO2 equivalent annually. This initiative not only contributes to carbon neutrality but also highlights the company's commitment to sustainable manufacturing practices.
Consumer Healthcare Growth
Despite challenges in the market, the India Consumer Healthcare (ICH) sector reported double-digit revenue growth for both Q3 and the nine months. Key power brands under ICH saw a growth of 19%, driven largely by strong performances in the healthcare and wellness product categories. Additionally, the e-commerce segment has expanded impressively, with online sales exceeding 40% growth, indicating a shift towards digital consumption patterns.
Future Outlook and Conference Call Announcement
Piramal Pharma is set to conduct a conference call with investors and analysts to elaborate on these results and discuss future strategies. This call is scheduled to take place in the coming weeks, providing an opportunity for stakeholders to gain insights into the company’s direction and priorities.
Frequently Asked Questions
What were the main drivers of revenue growth for Piramal Pharma?
The revenue growth was primarily fueled by strong performance in the CDMO business and an increase in sales from the Complex Hospital Generics and Consumer Healthcare segments.
How did Piramal Pharma manage its EBITDA margin?
Piramal managed its EBITDA margin through operational efficiencies, improved revenue mix, and cost optimization initiatives.
What sustainability initiatives has Piramal Pharma undertaken?
The company has converted its coal-fired boilers to biomass briquettes, significantly reducing greenhouse gas emissions and demonstrating its commitment to sustainability.
How has Piramal Pharma's consumer healthcare segment performed?
The consumer healthcare segment reported double-digit growth, primarily driven by strong performances in key brands and increased e-commerce sales.
Is there a conference call scheduled for discussing the financial results?
Yes, Piramal Pharma will host a conference call for analysts and investors to discuss the Q3 and 9M FY25 results, providing deeper insights into the company's performance and future strategies.
